Clinical pipeline
Target: Muscle Function
Immunis is planning a Phase 2 placebo-controlled clinical trial to continue safety assessments of IMMUNA and evaluate its efficacy in addressing muscle performance in seniors with sarcopenic obesity.
IMMUNA Benefits Muscle Function and Metabolism (Preclinical Data)
Immunis Scientific Advisory Board member, Professor Micah Drummond, published preclinical research in Aging Cell supporting that Immunis’ investigational secretome enhances muscle mass and strength in aged mouse models, while increasing metabolism and reducing fat.
Aged mice received intramuscular injections of IMMUNA twice a week, for four consecutive week, totaling 8 injections. Compared to control-treated, aged mice,
These preclinical data demonstrate that Immunis’ secretome increases metabolism without compromising muscle mass. Immunis is in the process of submitting an application to the U.S. Food and Drug Administration to conduct a Phase 2 clinical trial investigating IMMUNA on muscle function in patients with sarcopenic obesity.
Check out our publication below.
Stem cell secretome treatment improves whole-body metabolism, reduces adiposity, and promotes skeletal muscle function in aged mice
Fennel, Zachary J., Paul-Emile Bourrant, Anu Susan Kurian, Jonathan J. Petrocelli, Naomi M. M. P. de Hart, Elena M. Yee, Sihem Boudina, et al. “Stem Cell Secretome Treatment Improves Whole-Body Metabolism, Reduces Adiposity, and Promotes Skeletal Muscle Function in Aged Mice.” Aging Cell. (March 3, 2024): e14144. https://doi.org/10.1111/acel.14144.